LRRK2 and Parkinson disease: Post mortem investigations in Leucine-rich repeat kinase 2 (LRRK2)- and Parkin-related PD patients or in PD models with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) induced nigrostriatal neuronal loss and dopamine deficit show no LB occurrence [94].